Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics

    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.

    loading  Loading Related Articles